WO2007109129A3 - Methods for preparing complex multivalent immunogenic conjugates - Google Patents

Methods for preparing complex multivalent immunogenic conjugates Download PDF

Info

Publication number
WO2007109129A3
WO2007109129A3 PCT/US2007/006627 US2007006627W WO2007109129A3 WO 2007109129 A3 WO2007109129 A3 WO 2007109129A3 US 2007006627 W US2007006627 W US 2007006627W WO 2007109129 A3 WO2007109129 A3 WO 2007109129A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
immunogenic conjugates
multivalent immunogenic
complex multivalent
preparing complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/006627
Other languages
French (fr)
Other versions
WO2007109129A8 (en
WO2007109129A2 (en
Inventor
Che-Hung Robert Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR20157006038A priority Critical patent/KR20150038626A/en
Priority to BRPI0708849-3A priority patent/BRPI0708849B1/en
Priority to KR1020187006722A priority patent/KR101947794B1/en
Priority to CN200780009505.2A priority patent/CN101405028B/en
Priority to KR1020137031130A priority patent/KR20130135399A/en
Priority to KR1020087025441A priority patent/KR101411425B1/en
Priority to KR1020167008207A priority patent/KR101711903B1/en
Priority to KR1020177005151A priority patent/KR101838938B1/en
Priority to AU2007227504A priority patent/AU2007227504B2/en
Priority to CA2644724A priority patent/CA2644724C/en
Priority to EP07753268.7A priority patent/EP1993604B1/en
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of WO2007109129A2 publication Critical patent/WO2007109129A2/en
Publication of WO2007109129A3 publication Critical patent/WO2007109129A3/en
Publication of WO2007109129A8 publication Critical patent/WO2007109129A8/en
Priority to US12/283,894 priority patent/US8173135B2/en
Priority to ZA2008/07961A priority patent/ZA200807961B/en
Anticipated expiration legal-status Critical
Priority to US13/440,856 priority patent/US8557250B2/en
Priority to US13/960,691 priority patent/US9175033B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C07K1/084—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Methods for preparing complex multivalent immunogenic conjugates that includ simultaneously reacting a plurality or immunogenic-distinct polysaccharides with at least one protein to make the complex multivalent immunogenic conjugates. The simultaneous reaction involves reaction of a hydrazide group on one reactant with an aldehyde or cyanat ester group on the other reactant.
PCT/US2007/006627 2006-03-17 2007-03-16 Methods for preparing complex multivalent immunogenic conjugates Ceased WO2007109129A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
EP07753268.7A EP1993604B1 (en) 2006-03-17 2007-03-16 Methods for preparing complex multivalent immunogenic conjugates
KR1020187006722A KR101947794B1 (en) 2006-03-17 2007-03-16 Methods for preparing complex multivalent immunogenic conjugates
CN200780009505.2A CN101405028B (en) 2006-03-17 2007-03-16 Method for preparing complexed multivalent immunogenic conjugates
KR1020137031130A KR20130135399A (en) 2006-03-17 2007-03-16 Methods for preparing complex multivalent immunogenic conjugates
KR1020087025441A KR101411425B1 (en) 2006-03-17 2007-03-16 METHOD FOR MANUFACTURING COMBINED POLYPRIDING CONJUGATE
KR1020167008207A KR101711903B1 (en) 2006-03-17 2007-03-16 Methods for preparing complex multivalent immunogenic conjugates
KR1020177005151A KR101838938B1 (en) 2006-03-17 2007-03-16 Methods for preparing complex multivalent immunogenic conjugates
AU2007227504A AU2007227504B2 (en) 2006-03-17 2007-03-16 Methods for preparing complex multivalent immunogenic conjugates
CA2644724A CA2644724C (en) 2006-03-17 2007-03-16 Methods for preparing complex multivalent immunogenic conjugates
KR20157006038A KR20150038626A (en) 2006-03-17 2007-03-16 Methods for preparing complex multivalent immunogenic conjugates
BRPI0708849-3A BRPI0708849B1 (en) 2006-03-17 2007-03-16 Methods for the preparation of complex multivalent immunogenic conjugates, said conjugates, and pharmaceutical compositions
US12/283,894 US8173135B2 (en) 2006-03-17 2008-09-15 Methods for preparing complex multivalent immunogenic conjugates
ZA2008/07961A ZA200807961B (en) 2006-03-17 2008-09-16 Methods for preparing complex multivalent immunogenic conjugates
US13/440,856 US8557250B2 (en) 2006-03-17 2012-04-05 Methods for preparing complex multivalent immunogenic conjugates
US13/960,691 US9175033B2 (en) 2006-03-17 2013-08-06 Methods for preparing complex multivalent immunogenic conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78349006P 2006-03-17 2006-03-17
US60/783,490 2006-03-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/283,894 Continuation-In-Part US8173135B2 (en) 2006-03-17 2008-09-15 Methods for preparing complex multivalent immunogenic conjugates

Publications (3)

Publication Number Publication Date
WO2007109129A2 WO2007109129A2 (en) 2007-09-27
WO2007109129A3 true WO2007109129A3 (en) 2007-11-08
WO2007109129A8 WO2007109129A8 (en) 2008-03-06

Family

ID=38337858

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/006627 Ceased WO2007109129A2 (en) 2006-03-17 2007-03-16 Methods for preparing complex multivalent immunogenic conjugates

Country Status (9)

Country Link
US (3) US8173135B2 (en)
EP (2) EP1993604B1 (en)
KR (6) KR101711903B1 (en)
CN (1) CN101405028B (en)
AU (1) AU2007227504B2 (en)
BR (1) BRPI0708849B1 (en)
CA (1) CA2644724C (en)
WO (1) WO2007109129A2 (en)
ZA (1) ZA200807961B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110072A1 (en) * 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa IMMUNOGENIC COMPOSITION
KR101711903B1 (en) * 2006-03-17 2017-03-03 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 Methods for preparing complex multivalent immunogenic conjugates
EP2262480B1 (en) * 2008-03-04 2018-02-14 Liquidia Technologies, Inc. Immunomodulator particles
CA2836153C (en) 2009-12-17 2016-06-21 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
EP2538969A4 (en) * 2010-02-22 2013-11-27 Liquidia Technologies Inc Polysaccharide particle vaccines
PL2575870T3 (en) * 2010-06-04 2017-05-31 Wyeth Llc Vaccine formulations
WO2013171661A2 (en) * 2012-05-15 2013-11-21 Subhash V Kapre Adjuvant formulations and methods
CN104428008B (en) 2012-05-24 2020-10-09 美国政府(由卫生和人类服务部的部长所代表) Multivalent meningococcal conjugates and methods of making the conjugates
CN104487086B (en) * 2012-07-07 2019-08-30 巴拉特生物技术国际有限公司 Non-alcohol-free vaccine composition of animal origin and its preparation method
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11147863B2 (en) 2015-06-23 2021-10-19 Biological E Limited Multivalent pneumococcal conjugate vaccine
WO2018009906A1 (en) * 2016-07-08 2018-01-11 President And Fellows Of Harvard College Whole cell-protein conjugates and methods of making the same
BR112019003992A2 (en) 2016-09-02 2019-05-28 Sanofi Pasteur Inc neisseria meningitidis vaccine
NZ752348A (en) 2016-09-30 2022-11-25 Biological E Ltd Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN110366428B (en) 2016-12-30 2024-05-17 Vaxcyte公司 Polypeptide-antigen conjugates with unnatural amino acids
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2018227177A1 (en) 2017-06-10 2018-12-13 Inventprise, Llc Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
IL284349B2 (en) 2018-10-12 2025-06-01 Biological E Ltd Polyvalent polysaccharide-protein conjugate vaccine of spotted fever
CN111388741B (en) * 2020-04-01 2021-09-07 东华大学 Injectable self-healing antibacterial hydrogel dressing with preloaded polypeptide and preparation method thereof
WO2022035816A1 (en) 2020-08-10 2022-02-17 Inventprise, Llc Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
CN117643624A (en) * 2024-01-30 2024-03-05 成都康华生物制品股份有限公司 Preparation method of bivalent polysaccharide conjugate vaccine and bivalent polysaccharide conjugate vaccine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002948A1 (en) * 2003-05-07 2005-01-06 Ryall Robert P. Method of enhanced immunogenicity to meningococcal vaccination
WO2005037320A2 (en) * 2003-08-06 2005-04-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Process for preparing polysaccharide-protein conjugate vaccines
WO2005117965A1 (en) * 2004-06-04 2005-12-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for preparing immunogenic conjugates
WO2006077397A2 (en) * 2005-01-18 2006-07-27 Amura Therapeutics Limited Method of producing conjugate vaccines

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63295408A (en) * 1987-05-28 1988-12-01 Mitsubishi Gas Chem Co Inc Method for purifying aqueous hydrazine hydrate solution
US5066408A (en) * 1990-03-15 1991-11-19 Powell Jonathan S Means and method to treat swimming pool water
US5480643A (en) * 1991-10-16 1996-01-02 Ecolab Inc. Stable antimicrobial dialdehyde composition and methods of use
US5849301A (en) * 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
WO1995008348A1 (en) 1993-09-22 1995-03-30 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
GB9417532D0 (en) * 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
WO2000004922A1 (en) 1998-07-20 2000-02-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Vaccines against escherichia coli o157 infection
ATE459373T1 (en) * 1999-03-19 2010-03-15 Glaxosmithkline Biolog Sa VACCINE AGAINST CAPSULAR POLYSACCHARIDES OF STREPTOCOCCUS PNEUMONIAE
US6800728B2 (en) * 2000-03-22 2004-10-05 Solulink Biosciences, Inc. Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
SI21352A (en) * 2001-01-23 2004-06-30 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
JP2004534088A (en) * 2001-07-06 2004-11-11 スローン−ケッタリング・インスティテュート・フォア・キャンサー・リサーチ Multivalent conjugate vaccine for cancer
WO2004011027A1 (en) * 2002-07-30 2004-02-05 Baxter International Inc. Chimeric multivalent polysaccharide conjugate vaccines
CN1401328A (en) * 2002-10-18 2003-03-12 北京绿竹生物技术有限责任公司 Epidemic meningitis polyose-protein binding vaccine
CN1852733A (en) * 2003-05-07 2006-10-25 安万特巴斯德公司 Polyvalent meningococcal-derived polysaccharide-protein conjugates and vaccines
JP2007516181A (en) * 2003-06-23 2007-06-21 アヴェンティス パストゥール インコーポレイテッド Method for immunization against meningococcal serogroups A and C
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
KR101711903B1 (en) * 2006-03-17 2017-03-03 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 Methods for preparing complex multivalent immunogenic conjugates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002948A1 (en) * 2003-05-07 2005-01-06 Ryall Robert P. Method of enhanced immunogenicity to meningococcal vaccination
WO2005037320A2 (en) * 2003-08-06 2005-04-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Process for preparing polysaccharide-protein conjugate vaccines
WO2005117965A1 (en) * 2004-06-04 2005-12-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for preparing immunogenic conjugates
WO2006077397A2 (en) * 2005-01-18 2006-07-27 Amura Therapeutics Limited Method of producing conjugate vaccines

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CARMENATE TANIA ET AL: "Effect of conjugation methodology on the immunogenicity and protective efficacy of meningococcal group C polysaccharide-P64k protein conjugates", FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, ELSEVIER SCIENCE B.V., AMSTERDAM, NL, vol. 40, no. 3, 9 April 2004 (2004-04-09), pages 193 - 199, XP002314674, ISSN: 0928-8244 *
GUPTA R K ET AL: "Comparative Immunogenicity of Conjugates Composed of Escherichia coli O111 O-Specific Polysaccharide, Prepared by Treatment with Acetic Acid or Hydrazine, Bound to Tetanus Toxoid by Two Synthetic Schemes", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 63, no. 8, August 1995 (1995-08-01), pages 2805 - 2810, XP002103338, ISSN: 0019-9567 *
KONADU E ET AL: "PREPARATION, CHARACTERIZATION, AND IMMUNOLOGICAL PROPERTIES IN MICE OF ESCHERICHIA COLI O157 O-SPECIFIC POLYSACCHARIDE-PROTEIN CONJUGATE VACCINES", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 62, no. 11, November 1994 (1994-11-01), pages 5048 - 5054, XP002912809, ISSN: 0019-9567 *
SHEN X ET AL: "Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization.", INFECTION AND IMMUNITY JAN 2001, vol. 69, no. 1, January 2001 (2001-01-01), pages 297 - 306, XP002447181, ISSN: 0019-9567 *
TE PIAO KING ET AL: "PREPARATION OF PROTEIN CONJUGATES VIA INTERMOLECULAR HYDRAZONE LINKAGE", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 25, 1986, pages 5774 - 5779, XP001015547, ISSN: 0006-2960 *

Also Published As

Publication number Publication date
KR101947794B1 (en) 2019-02-13
KR20180028558A (en) 2018-03-16
US20140044748A1 (en) 2014-02-13
KR20130135399A (en) 2013-12-10
AU2007227504B2 (en) 2013-10-31
WO2007109129A8 (en) 2008-03-06
KR20160038086A (en) 2016-04-06
AU2007227504A2 (en) 2008-10-30
CN101405028B (en) 2015-08-19
KR101711903B1 (en) 2017-03-03
US9175033B2 (en) 2015-11-03
WO2007109129A2 (en) 2007-09-27
EP1993604B1 (en) 2015-12-02
KR101411425B1 (en) 2014-06-24
ZA200807961B (en) 2015-04-29
CN101405028A (en) 2009-04-08
BRPI0708849B1 (en) 2022-05-17
EP3006041B1 (en) 2017-11-29
KR20150038626A (en) 2015-04-08
CA2644724C (en) 2016-05-24
CA2644724A1 (en) 2007-09-27
KR20080103604A (en) 2008-11-27
KR101838938B1 (en) 2018-03-15
US20090092632A1 (en) 2009-04-09
EP1993604A2 (en) 2008-11-26
US20120195922A1 (en) 2012-08-02
US8557250B2 (en) 2013-10-15
KR20170024141A (en) 2017-03-06
AU2007227504A1 (en) 2007-09-27
BRPI0708849A2 (en) 2011-06-21
US8173135B2 (en) 2012-05-08
EP3006041A1 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
WO2007109129A8 (en) Methods for preparing complex multivalent immunogenic conjugates
IL242665B (en) A process for producing anti-tricyclo[3.2.2.0]non-6-ene-endo-8,endo-9-dicarboxylic acid anhydride
WO2005014037A3 (en) Polysaccharide-protein conjugate vaccines
WO2007112193A3 (en) Camptothecin-binding moiety conjugates
WO2008103693A3 (en) Chemical linkers with single amino acids and conjugates thereof
WO2008022777A3 (en) Process for preparing 3-dihalomethylpyrazole-4-carboxylic acid derivatives
WO2007133855A3 (en) Glycoprotein synthesis and remodeling by enzymatic transglycosylation
WO2007122405A8 (en) Polyhedral nanostructures formed from nucleic acids
MX2009000520A (en) Methods for producing fuels and solvents.
WO2009042070A3 (en) Production of isoprenoids
WO2007144424A3 (en) Processes for production of a starch hydrolysate
WO2009016257A3 (en) Method for producing an acidified milk drink
WO2009100995A3 (en) Storage-stable product systems for premix formulations
WO2008024716A3 (en) Process of making alkyl esters of free fatty acids
WO2010110599A3 (en) Novel αlpha-neoagarobiose hydrolase, and method for obtaining a monosaccharide using same
WO2008017079A3 (en) Dyes and precursors and conjugates thereof
WO2010014258A3 (en) Conjugates having a releasable linkage
WO2013170963A3 (en) Enzymatic synthesis of l-nucleic acids
WO2010048389A3 (en) Vaginal pellets comprising debranched starch
WO2008049183A8 (en) Method for modifying plant architecture and enhancing plant biomass and/or sucrose yield
WO2010089376A3 (en) Method for producing an acidified milk product
WO2009147103A3 (en) Method for producing a wheat protein hydrolysate
WO2009150543A3 (en) Conjugated vi saccharides
MX2009006479A (en) Hemicellulose derivatives and structures employing same.
WO2007143152A3 (en) Preparation of (s)-pregabalin-nitrile

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07753268

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2644724

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 3682/KOLNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007227504

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200780009505.2

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007753268

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007227504

Country of ref document: AU

Date of ref document: 20070316

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020087025441

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0708849

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080917

WWE Wipo information: entry into national phase

Ref document number: 1020157006038

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1020167008207

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1020177005151

Country of ref document: KR